RNA malaria vaccine shows promise in early human trial

NCT ID NCT06069544

First seen Apr 18, 2026 · Last updated May 03, 2026 · Updated 2 times

Summary

This study tested an experimental RNA-based vaccine (BNT165e) to prevent malaria in 163 healthy adults who had never had malaria. The vaccine uses three RNA pieces to train the immune system against the malaria parasite. Researchers checked for side effects and measured immune responses after vaccination and a controlled malaria infection. The goal is to see if the vaccine is safe and can protect against malaria.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AMR Knoxville

    Knoxville, Tennessee, 37909, United States

  • AMR Las Vegas

    Las Vegas, Nevada, 89119, United States

  • AMR Tempe

    Tempe, Arizona, 85281, United States

  • Clinical Trials of Texas

    San Antonio, Texas, 78229, United States

  • University of Maryland, Center for Vaccine Development

    Baltimore, Maryland, 21201, United States

Conditions

Explore the condition pages connected to this study.